HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Gain Therapeutics (NASDAQ:GANX) and maintained a $10 price target.
September 18, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Gain Therapeutics (NASDAQ:GANX) and maintained a $10 price target.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Gain Therapeutics. The maintained price target of $10 also indicates the firm's confidence in the stock's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100